검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belumosudil |
Overview Company | Sanofi |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Plasma Cell Myeloma Refractory |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting B cell signalling, JAK-STAT, ROCK2 and CSF1R pathway |
MoA Biomarker | Biomarkers for early diagnosis and personalized treatment remain under investigation |
PK/PD Half-life | 19 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography.. Belumosudil is an oral, selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2, approved for the treatment of chronic graft-versus-host disease (cGVHD). Clinical trials have shown that higher doses of belumosudil are associated with a greate… |
Clinical Primary efficacy | ORR 74% |
Clinical ORR | 74.0% |
Clinical Result source | ClinicalTrials.gov NCT03640481 |
Clinical Data Tier / Score | A · 58 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belumosudil |
Overview Company | Sanofi |
Overview Modality | ADC |
Overview Target | FRα |
Overview Indication | Plasma Cell Myeloma Refractory |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting B cell signalling, JAK-STAT, ROCK2 and CSF1R pathway |
MoA Biomarker | Biomarkers for early diagnosis and personalized treatment remain under investigation |
PK/PD Half-life | 19 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography.. Belumosudil is an oral, selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2, approved for the treatment of chronic graft-versus-host disease (cGVHD). Clinical trials have shown that higher doses of belumosudil are associated with a greate… |
Clinical Primary efficacy | ORR 74% |
Clinical ORR | 74.0% |
Clinical Result source | ClinicalTrials.gov NCT03640481 |
Clinical Data Tier / Score | A · 58 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교